Radius Health (RDUS) Gives Presentation on Abaloparatide Transdermal Patch Development Program at ASBMR
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Radius Health Inc. (Nasdaq: RDUS) a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases today gave an oral presentation at the Late-Breaking Abstract Session titled “Clinical Development of an Optimized Abaloparatide Transdermal Patch” at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting, at the Georgia World Congress Center in Atlanta, Georgia.
”This is the first successful application of formulation technology to enable alterations in the pharmacokinetic profile of transdermally delivered abaloparatide in post menopausal women,” said Dr. Gary Hattersley, Chief Scientific Officer of Radius Health. “We believe the results from these pilot pharmacokinetic studies place us firmly on the path to establishing comparable drug exposure to subcutaneous abaloparatide.”
Radius presented results from the pilot pharmacokinetic studies of the second generation transdermal patch in postmenopausal women demonstrating the targeted changes in the time to peak concentration (Tmax); half life (T1/2) and area under the curve (AUC). These results establish the basis for selection of the transdermal patch formulation for bioequivalence studies.
The presentation included a report on the overall safety profile of the first generation transdermal patch in the completed six month Phase 2 bone mineral density study where there was a similar incidence of treatment emergent adverse events across the subcutaneous and transdermal dose groups. As previously reported, the first generation transdermal patch demonstrated a unique and pulsatile pharmacokinetic profile and resulted in dose proportionate increases in bone mineral density when patients self administered the patch over the six month duration of the study.
Radius initiated a second generation program to apply formulation technology in developing multiple transdermal patch alternatives that were screened in a nonhuman primate model for changes in the pharmacokinetic profile. These primate studies identified second generation transdermal patches with the potential to achieve bioequivalence to the subcutaneous administration of abaloparatide. The pilot pharmacokinetic studies were initiated to replicate these findings after single dose administration in the postmenopausal subjects.
The pilot pharmacokinetic studies establish a basis for Radius to select an optimized second generation transdermal patch and to design a formal bioequivalence study. Final selection of the optimized patch will include an evaluation of manufacturing, stability, and other considerations as required to meet regulatory requirements.
About Postmenopausal Osteoporosis
Osteoporosis is a silent disease, often displaying no signs or symptoms until a fracture occurs, leaving a majority of patients undiagnosed and undertreated. Osteoporotic fractures create a significant healthcare burden, and represent a significant unmet medical need. An estimated two million osteoporotic fractures occur annually in the U.S., and this number is projected to grow to three million by 2025.
The National Osteoporosis Foundation (NOF) has estimated that 10 million people in the U.S., composed of eight million women and two million men, already have osteoporosis, and another approximately 44 million people have low bone mass placing them at increased risk for osteoporosis.
The debilitating effects of osteoporosis have substantial costs. When left untreated, osteoporosis leads to fractures which can have both physical and emotional consequences on a patient including pain and disability, inability to fully perform routine work or daily activities, and in some cases, result in death.
The Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial was a randomized, double-blind, placebo-controlled, comparative, multicenter, 18 month international study in 2,463 postmenopausal women with osteoporosis designed to evaluate the efficacy and safety of the investigational drug abaloparatide-SC 80 mcg to reduce the risk of vertebral and nonvertebral fractures. Miller PD et al, “Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis, A Randomized Clinical Trial” Journal of the American Medical Association 2016 Aug 16;316(7):722-733.
Abaloparatide is an investigational therapy for the potential treatment of postmenopausal women with osteoporosis. Abaloparatide is a novel peptide that engages the parathyroid hormone receptor (PTH1 receptor) and was selected for clinical development based on its favorable bone building activity.
Abaloparatide has completed Phase 3 development for potential use as a daily self-administered injection (abaloparatide-SC). In the fourth quarter of 2015, Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of patients with postmenopausal osteoporosis was validated and is currently undergoing regulatory review by the European Medicines Agency (EMA). Radius submitted a New Drug Application (NDA) for abaloparatide-SC to the US Food and Drug Administration (FDA) at the end of the first quarter of 2016, which has been accepted for filing with a PDUFA date of March 30, 2017. Radius also is developing abaloparatide-transdermal (abaloparatide-TD) based on 3M's patented Microstructured Transdermal System technology for potential use as a treatment for postmenopausal women with osteoporosis.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Radius Health (RDUS) Announces Positive Data from Two RAD1901 Phase 1s in SERD
- Cellular Biomedicine Group (CBMG) AlloJoin AE from Phase I Similar to Prior Autologous Trial
- Cytokinetics (CYTK) Presents Data from VITALITY-ALS at International Symposium